Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of SERT Inhibition on LSD Response
NCT05175430Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) and anxiety disorder comparing Paroxetine Condition with Placebo Condition (2 arms). Primary endpoints: 5 Dimensions of Altered State of Consciousness Total Score and Visual Analog Scale Good Effect Rating. Started Oct 2022; status: completed.
02
Drugs
paroxetine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT05175430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175430.